American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced completion of the pilot runs of its HIV Functional Cure automated cell processing protocol. This completes a key milestone of AGT’s planned Phase I clinical trial of AGT103-T, a genetically modified autologous T cell product in development as an HIV functional cure.
{iframe}https://www.americangene.com/american-gene-technologies-announces-progress-toward-phase-clinical-trial-agt103-t-hiv-functional-cure/{/iframe}